Safety of bevacizumab in mild haemophilia B

Thrombosis and Haemostasis

Volumn 99, Issue 5, 2008, Pages 963-964

  Lambert, Catherine ^a   Deneys, Véronique ^a   Pothen, Dominique ^a   Hermans, Cedric ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; RECOMBINANT BLOOD CLOTTING FACTOR 9;

AGED; ARTICLE; BLEEDING; CANCER CHEMOTHERAPY; CANCER MORTALITY; CASE REPORT; COLON CARCINOMA; COLON RESECTION; COMBINATION CHEMOTHERAPY; DISEASE COURSE; DISEASE SEVERITY; DRUG SAFETY; FOLLOW UP; HEMOPHILIA B; HUMAN; LABORATORY TEST; LIVER METASTASIS; MALE; PRIORITY JOURNAL; THROMBOELASTOGRAPHY; TREATMENT OUTCOME;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; HEMOPHILIA B; HEMORRHAGE; HEMOSTASIS; HUMANS; LIVER NEOPLASMS; MALE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 43949099647     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH07-12-0717     Document Type: Article

References (13)

1. Hurwitz H, et al. Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for metastatic colorectal cancer. N Engl Med 2004; 350: 2335-2342.
2. Kabbinavar FF, et al. Combined analysis of efficacy : the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005; 23: 3706-3712.
3. Kabbinavar FF, et al. Phase II randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21: 60-65.
4. Kabbinavar FF, et al. Addition of bevacizumab to bolus 5FU/leucorvin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005; 23: 3697-3705.
5. Saif MW, Mehra R. Incidence and management of bevacizumab-related toxicities in colorectal cancer. Expert Opnin Drug Saf 2006; 5: 553-566.
6. Hoff PM, et al. Preliminary results from a phase II study of FOLFIRI plus bevacizumab (Avastin) as first-line treatment for metastatic colorectal cancer. Proc Am Soc Clin Oncol Gastroenterol Symp 2006; 252 (Abstract).
7. National Cancer Institute Common toxicity criteria manual version 2. http://www.ctep.cancer.gov/forms/CTCManual_v4_10-4-99.pdf
8. Kretzschmar A, et al. First BEAT Investigators. Incidence of gastro-intestinal perforations and bleeding in patients starting bevacizumab treatment in first-line mCRC without primary tumour resection: Preliminary results from the first BEAT trial. Proc Am Soc Clin Oncol Gastroenterol Symp 2006; 248 (Abstract).
9. Hambleton J, et al. Safety of low-dose aspirin in a pooled analysis of 3 randomized, controlled trials of bevacizumab with chemotherapy in patients with metastatic colorectal cancer. J Clin Oncol 2005; 23 (Suppl): Abstract 3554.
10. Hambleton J, et al. Bevacizumab does not increase bleeding in patients with metastatic colorectal cancer receiving concurrent anticoagulation. J Clin Oncol 2004; 22 (Suppl): Abstract 3528.
11. Hurwitz H, et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 2005; 23: 3502-3508.
12. Kabbinavar FF, et al. Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) to prolong progression-free survival in first-line colorectal cancer in subject who are not suitable candidates for first-line CPT-11. J Clin Oncol 2004; 22: 3516.
13. Kozloff M, et al. Safety of bevacizumab among patients receiving first-line chemotherapy for line metastatic colorectal cancer-updated results from a large observational study in the US (BRITE). Proc Am Soc Clin Oncol Gastroenterol Symp 2006; 247 (Abstract).